Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
The Lancet. Oncology
|
June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
Marcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
The Oncologist
|
October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
Umut Disel, Russell Madison, Kumar Abhishek, et al.
The New England Journal of Medicine
|
June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in Cancer
Mark M Awad, Shengwu Liu, Igor I Rybkin, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Shun Lu, Qiming Wang, Guojun Zhang, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
The Lancet. Oncology
|
June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
Marcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
The Oncologist
|
October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
Umut Disel, Russell Madison, Kumar Abhishek, et al.
The New England Journal of Medicine
|
June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in Cancer
Mark M Awad, Shengwu Liu, Igor I Rybkin, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Shun Lu, Qiming Wang, Guojun Zhang, et al.
Page
of 5